All In Biotech

Drug Trial Radar · NCT03652077

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 24, 2018

Primary completion

Aug 18, 2021

Study completion Aug 18, 2021

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Aug 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

Conditions

  • Cervical Cancer
  • Gastric Cancer
  • Stomach Cancer
  • Gastroesophageal Junction Cancer
  • Esophageal Cancer
  • Hepatocellular Carcinoma
  • Melanoma
  • Uveal Melanoma
  • Merkel Cell Carcinoma
  • Mesothelioma
  • MSI
  • Non-small Cell Lung Cancer
  • NSCLC
  • Ovarian Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • RCC
  • Triple-negative Breast Cancer
  • Urothelial Carcinoma
  • Mismatch Repair Deficiency

Interventions

  • INCAGN02390Drug

    Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-emergent adverse eventsTime frame: Up to 12 months
  2. Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only)Time frame: Up to approximately 1 month

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The Angeles Clinical and Research Institute

    Los Angeles, California

  • University of Mississippi

    Jackson, Mississippi

  • Hackensack Medical Center

    Hackensack, New Jersey

  • Carolina BioOncology

    Huntsville, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.